Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

Active, not recruitingOBSERVATIONAL
Enrollment

170

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Trial Locations (12)

SM2 5PT

The Royal Marsden Hospital, Sutton

HP21 8AL

Buckinghamshire Healthcare NHS Trust, Aylesbury

BT9 7AB

Northern Ireland Cancer Centre, Belfast Health & Social Care Trust, Belfast

BB2 3HH

East Lancashire Hospitals NHS Trust, Blackburn

CB2 0QQ

Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge

CF14 2TL

Velindre Cancer Centre, Velindre University NHS Trust, Cardiff

LA1 4RP

University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster

CH63 4JY

Clatterbrdige Cancer Centre, NHS Foundation Trust, Liverpool

TS4 3BW

The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough

NE34 0PL

South Tyneside and Sunderland NHS Foundation Trust, Newcastle

NE7 7DN

Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle

TS19 8PE

The University Hospital of North Tees, Stockton-on-Tees

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT06019676 - Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | Biotech Hunter | Biotech Hunter